DND PharmaTech Inc (347850)

Currency in KRW
37,750
-2,800(-6.91%)
Closed·
347850 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
36,65039,150
52 wk Range
34,500116,600
Key Statistics
Bid/Ask
37,850.00 / 37,900.00
Prev. Close
37,750
Open
37,150
Day's Range
36,650-39,150
52 wk Range
34,500-116,600
Volume
689.45K
Average Vol. (3m)
655.35K
1-Year Change
-49.4983%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
347850 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with high price volatility

DND PharmaTech Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Earnings

Latest Release
Aug 14, 2026
EPS / Forecast
-187.00 / --
Revenue / Forecast
662.06M / --
EPS Revisions
Last 90 days

347850 Income Statement

Compare 347850 to Peers and Sector

Metrics to compare
347850
Peers
Sector
Relationship
P/E Ratio
−80.1x−11.3x−0.2x
PEG Ratio
−13.890.000.00
Price / Book
12.8x2.7x2.6x
Price / LTM Sales
629.1x15.1x2.8x
Upside (Analyst Target)
-170.3%65.6%
Fair Value Upside
Unlock19.7%10.0%Unlock

D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson’s and Alzheimer’s diseases. The company is also involved in the development of TLY012, an injectable protein for systemic sclerosis, liver fibrosis, and chronic pancreatitis indications; NLY02, an oral small molecule for PD and AD indications; and P4M01 for anti-microbial peptide indications. In addition, it develops PMI07, PMI05, and PMI06 for solid tumor imaging biomarker indications; and PMI04 for neuroinflammation indications. The company was founded in 2014 and is based in Seongnam-si, South Korea.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
2.21M4.82%85.77B
Other Institutional Investors
12.37M27.00%480.77B
Public Companies & Retail Investors
31.25M68.19%1.21T
Total
45.84M100.00%1.78T

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Rebright Holdings Limited Liability Company4.52%2,071,60080,481,660
InterVest4.17%1,911,90874,277,626

People Also Watch

62,200
457190
-10.76%
13,980
077970
-5.35%
4,255
010820
-5.13%
8,140
056080
-4.01%
7,280
050890
-5.21%

FAQ

What Is the DND PharmaTech (347850) Stock Price Today?

The DND PharmaTech stock price today is 37,750 KRW.

What Stock Exchange Does DND PharmaTech Trade On?

DND PharmaTech is listed and trades on the KOSDAQ.

What Is the Stock Symbol for DND PharmaTech?

The stock symbol for DND PharmaTech is "347850."

What Is the DND PharmaTech Market Cap?

As of today, DND PharmaTech market cap is 1.73T KRW.

What Is DND PharmaTech's Earnings Per Share (TTM)?

The DND PharmaTech EPS (TTM) is -494.89.

From a Technical Analysis Perspective, Is 347850 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has DND PharmaTech Stock Split?

DND PharmaTech has split 1 times.

How Many Employees Does DND PharmaTech Have?

DND PharmaTech has 25 employees.

What is the current trading status of DND PharmaTech (347850)?

As of Nov 07, 2026, DND PharmaTech (347850) is trading at a price of 37,750 KRW, with a previous close of 37,750 KRW. The stock has fluctuated within a day range of 36,650 KRW to 39,150 KRW, while its 52-week range spans from 34,500 KRW to 116,600 KRW.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.